Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 91 of 5804
-
Promising new combo therapy for advanced prostate cancer enters final testing phase
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a c…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lupus shot shows promise in major trial
Disease control OngoingThe purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Balloon in the aorta could boost CPR success in cardiac arrest
Disease control OngoingThe primary aim of this trial is to assess the efficacy of resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct treatment to advanced cardiovascular life support (ACLS) in patients with out-of-hospital cardiac arrest. Out of hospital cardiac arrest (OH…
Phase: NA • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug zilganersen aims to slow rare brain disease
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-cont…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for glioblastoma: experimental drug berubicin faces key trial
Disease control OngoingThis is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will inclu…
Phase: PHASE2 • Sponsor: CNS Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising combo targets genetic weakness in prostate cancer
Disease control OngoingThe purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough esophageal cancer
Disease control OngoingThis is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chem…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy shows promise for tough-to-treat lymphoma
Disease control OngoingThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for High-Risk breast cancer: immunotherapy plus targeted drug tested in major trial
Disease control OngoingThis is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual in…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One-Time gene injection aims to slow rare fatal brain disease in kids
Disease control OngoingThis is a phase 1 open-label, single-administration of gene therapy agent AAV9/CLN7, administered intrathecally into the lumbar spinal cord region of pediatric patients with CLN7 Batten disease. This study consists of a one-time injection of AAV9/CLN7. There are two Cohorts with…
Phase: PHASE1 • Sponsor: Benjamin Greenberg • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for bladder cancer: immunotherapy may delay recurrence in High-Risk patients
Disease control OngoingThis is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive an…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThe goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug cocktail aims to beat bladder cancer recurrence
Disease control OngoingThe purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabin…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Massive global study aims to slash TB deaths with smarter testing
Diagnosis Recruiting nowTo reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. T…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New hope for advanced kidney cancer: Triple-Drug combo shows promise
Disease control OngoingThe goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for myelofibrosis patients who fail current treatments
Disease control OngoingThe purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Phase: PHASE3 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New RSV shot shows promise in protecting infants
Prevention CompletedThe primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial vi…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to outperform keytruda in lung cancer
Disease control CompletedResearchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive. * Metastatic means cancer that has spread to other parts of the body. * PD-L1 positive means that PD-L1 is found on the cancer cells. PD-L1 is a protei…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could Lab-Grown brain cells ease Parkinson's?
Disease control Recruiting nowThis is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Phase: PHASE1 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC